Welcome to BioMarket Group!

Drug Pipeline Updates

In this section you will find Publication Series Analytical Tool Drug Pipeline Updates market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 51 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4

Set Ascending Direction
  1. Lymphoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 383 companies plus partners who are today developing 568 lymphoma drugs in 1073 developmental projects in cancer across 302 different targets. In addition, there are 4 suspended drugs and another 143 drugs where development has been ceased. Learn More

  2. Head and Neck Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 214 companies plus partners who are today developing 236 drugs targeting head and neck cancer in development. across 222 different targets. In addition, there are 2 suspended drugs and another 59 drugs where development has been ceased. Learn More

  3. Wnt Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 228 companies plus partners who are today developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer across 204 different targets. In addition, there are 2 suspended drugs and another 118 drugs where development has been ceased. Learn More

  4. Melanoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 374 companies plus partners who are today developing 403 drugs targeting melanoma in development. across 317 different targets. In addition, there are 2 suspended drugs and another 155 drugs where development has been ceased. Learn More

  5. Proteins in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More

  6. IL-3 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More

  7. Peptides in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 340 companies plus partners who are today developing 356 peptide drugs in 778 developmental projects in cancer across 252 different targets. In addition, there are 4 suspended drugs and another 148 drugs where development has been ceased. Learn More

  8. Hedgehog Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 163 companies plus partners who are today developing 203 Hedgehog pathway targeting drugs in 883 developmental projects in cancer across 133 different targets. In addition, there are 3 suspended drugs and another 90 drugs where development has been ceased. Learn More

  9. Apoptosis in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 460 companies plus partners who are today developing 588 apoptotic drugs in 2586 developmental projects in cancer across 389 different targets. In addition, there are 13 suspended drugs and another 307 drugs where development has been ceased. Learn More

  10. Cellular Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 164 companies plus partners who are today developing 272 cellular therapy drugs in 577 developmental projects in cancer across 92 different targets. In addition, there are 7 suspended drugs and another 66 drugs where development has been ceased. Learn More

  11. IL-1 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 111 companies plus partners who are today developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer across 96 different targets. In addition, there are 2 suspended drugs and another 55 drugs where development has been ceased. Learn More

  12. Angiogenesis in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 389 companies plus partners who are today developing 428 angiogenesis drugs in 1991 developmental projects in cancer across 288 different targets. In addition, there are 7 suspended drugs and another 218 drugs where development has been ceased. Learn More

  13. Liver Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 260 companies plus partners who are today developing 280 drugs targeting liver cancer in development. across 221 different targets. In addition, there is 1 suspended drug and another 65 drugs where development has been ceased. Learn More

  14. Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 534 Alpha6Beta4 integrin pathway targeting drugs in 1796 developmental projects in cancer across 186 different targets. In addition, there is 1 suspended drug and another 209 drugs where development has been ceased. Learn More

  15. IL-9 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 83 companies plus partners who are today developing 88 IL-9 pathway targeting drugs in 366 developmental projects in cancer across 67 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

Items 1 to 15 of 51 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4

Set Ascending Direction

Drug Pipeline Updates

In this section you will find Publication Series Analytical Tool Drug Pipeline Updates market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

Items 1 to 15 of 51 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4

Set Ascending Direction
  1. Lymphoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 383 companies plus partners who are today developing 568 lymphoma drugs in 1073 developmental projects in cancer across 302 different targets. In addition, there are 4 suspended drugs and another 143 drugs where development has been ceased. Learn More

  2. Head and Neck Cancer Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 214 companies plus partners who are today developing 236 drugs targeting head and neck cancer in development. across 222 different targets. In addition, there are 2 suspended drugs and another 59 drugs where development has been ceased. Learn More

  3. Wnt Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 228 companies plus partners who are today developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer across 204 different targets. In addition, there are 2 suspended drugs and another 118 drugs where development has been ceased. Learn More

  4. Melanoma Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 374 companies plus partners who are today developing 403 drugs targeting melanoma in development. across 317 different targets. In addition, there are 2 suspended drugs and another 155 drugs where development has been ceased. Learn More

  5. Proteins in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 455 companies plus partners who are today developing 521 protein drugs in 914 developmental projects in cancer across 229 different targets. In addition, there are 2 suspended drugs and another 207 drugs where development has been ceased. Learn More

  6. IL-3 Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 257 companies plus partners who are today developing 339 IL-3 pathway targeting drugs in 1225 developmental projects in cancer across 164 different targets. In addition, there are 4 suspended drugs and another 131 drugs where development has been ceased. Learn More

  7. Peptides in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 340 companies plus partners who are today developing 356 peptide drugs in 778 developmental projects in cancer across 252 different targets. In addition, there are 4 suspended drugs and another 148 drugs where development has been ceased. Learn More

  8. Hedgehog Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 163 companies plus partners who are today developing 203 Hedgehog pathway targeting drugs in 883 developmental projects in cancer across 133 different targets. In addition, there are 3 suspended drugs and another 90 drugs where development has been ceased. Learn More

  9. Apoptosis in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 460 companies plus partners who are today developing 588 apoptotic drugs in 2586 developmental projects in cancer across 389 different targets. In addition, there are 13 suspended drugs and another 307 drugs where development has been ceased. Learn More

  10. Cellular Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 164 companies plus partners who are today developing 272 cellular therapy drugs in 577 developmental projects in cancer across 92 different targets. In addition, there are 7 suspended drugs and another 66 drugs where development has been ceased. Learn More

  11. IL-1 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 111 companies plus partners who are today developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer across 96 different targets. In addition, there are 2 suspended drugs and another 55 drugs where development has been ceased. Learn More

  12. Angiogenesis in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 389 companies plus partners who are today developing 428 angiogenesis drugs in 1991 developmental projects in cancer across 288 different targets. In addition, there are 7 suspended drugs and another 218 drugs where development has been ceased. Learn More

  13. Liver Cancer Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 260 companies plus partners who are today developing 280 drugs targeting liver cancer in development. across 221 different targets. In addition, there is 1 suspended drug and another 65 drugs where development has been ceased. Learn More

  14. Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 378 companies plus partners who are today developing 534 Alpha6Beta4 integrin pathway targeting drugs in 1796 developmental projects in cancer across 186 different targets. In addition, there is 1 suspended drug and another 209 drugs where development has been ceased. Learn More

  15. IL-9 Signaling Pathway in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 83 companies plus partners who are today developing 88 IL-9 pathway targeting drugs in 366 developmental projects in cancer across 67 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More

Items 1 to 15 of 51 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4

Set Ascending Direction